Compare AMPG & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | ACRV |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 52.4M |
| IPO Year | N/A | 2022 |
| Metric | AMPG | ACRV |
|---|---|---|
| Price | $2.21 | $2.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $11.67 |
| AVG Volume (30 Days) | 447.6K | ★ 835.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102.41 | N/A |
| Revenue Next Year | $20.00 | $568.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $1.05 |
| 52 Week High | $4.89 | $3.56 |
| Indicator | AMPG | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 61.76 |
| Support Level | $1.81 | $1.49 |
| Resistance Level | $2.83 | $2.19 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 73.75 | 62.24 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. It operates in two segments: the manufacturing and engineering segment. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.